Home » Topics » BioWorld Science

BioWorld Science
RSS

Betta Pharmaceuticals discloses new HIF-2alpha inhibitors

Jan. 11, 2022

Surrozen advances research pipeline targeting Wnt pathway

Jan. 11, 2022

AC Immune synthesizes NLRP3 inflammasome inhibitors

Jan. 11, 2022

Researchers present new F-BODIPY dyes for cancer

Jan. 11, 2022

Sato Pharmaceutical patents new HPGDS inhibitors

Jan. 11, 2022

Century and Bristol Myers Squibb collaborate to develop iPSC-derived allogeneic cell therapies

Jan. 11, 2022

Autobahn Therapeutics discloses thyroid hormone receptor agonists

Jan. 11, 2022

InflaRx advances oral C5aR inhibitor INF-904 toward clinic

Jan. 11, 2022

Regulation of SWI/SNF complex SMARCA2/4 subunits for treating enhancer-addicted prostate cancer

Jan. 11, 2022

Researchers find novel PTSD-related biomarkers

Jan. 11, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 1, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
New evidence links autoimmunity to long COVID symptoms
BioWorld
Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that...
Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections
BioWorld
GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...